US Patent

US8114874 — Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors

Composition of Matter · Assigned to Ariad Pharmaceuticals Inc · Expires 2027-01-24 · 1y remaining

Vulnerability score 27/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a class of compounds, specifically substituted acetylenic imidazo[1,2-b]pyridazine compounds, as kinase inhibitors.

USPTO Abstract

This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use. In particular, the compounds include embodiments in which Ring T is an imidazo[1,2-b]pyridazine ring system, Rings A and B are each aryl and L 1 is —C(O)NR 1 — or —NR 1 C(O)—. Uses for the compounds and for compositions containing them include treatment of cancer and other diseases mediated by protein kinases.

Drugs covered by this patent

Patent Metadata

Patent number
US8114874
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-01-24
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Ariad Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.